Donald Trump threatens “major tariff” on pharmaceuticals.

Lore Gruenbaum tells us about her career spanning big pharma, biotech and now The Leukemia & Lymphoma Society.

Job cuts at the FDA spark concern, with Robert Califf saying the agency as we know it is “finished.”

We ask James Chambers from Tufts Medical Center about the challenges faced by biosimilars in the US.

Here’s how researchers took lessons from cephalopods to develop a new capsule that can deliver drugs, including insulin and siRNA, orally.

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr.

Indian CDMO denies manufacturing drug, contract testing lab pulled up for deficiencies, and lessons learned from Sanofi’s warning letter.

How antisense oligonucleotides open up targeted approaches to rare disease treatment.

Long-acting injectables help with adherence, but what if an unfolding pill could provide an oral option?

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report